Zanvexus

A new drug, iberdomide (Zanvexus), has been approved by the FDA for the treatment of adults with relapsed or refractory multiple myeloma. Its combination with other drugs nearly doubled the rate of patients in whom no evidence of the disease was found. It is still unclear whether this will translate into extended life. Dr. Julia Vaksman, from the Hematology Department at the Davidoff Center in...